LA JOLLA, Calif., Aug. 19 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) ("Duska") announced today that its CEO, James S. Kuo, M.D., M.B.A. will present at the fourth annual Noble Financial Equity Conference on Tuesday, August 19, 2008 at the Loews Lake Las Vegas Resort in Las Vegas, Nevada. Duska's presentation is scheduled for 1:30 p.m. PDT. Dr. Kuo will also be available for one-on-one meetings throughout the day.
The presentation with streaming video and PowerPoint will be webcast live and archived on Noble Financial's conference website at http://www.noblemadmax.com. Participants should register at least 10 minutes prior to the start of the presentation to ensure timely access.
About Duska Therapeutics, Inc.
Duska Therapeutics, Inc. (Duska) is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging new pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which by several pharmaceuticals constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Duska is developing a portfolio of investigational medicines, two of which are in late stages of clinical testing. Duska's ATPace(TM) is expected to enter a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia. Duska's CDP-1050 is expected to commence a Phase 2 clinical trial for the treatment of heart failure. In addition, Duska has a preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For more information, visit http://www.duskatherapeutics.com.
This press release co
|SOURCE Duska Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved